MITOTOX

Drug

D0033 | Dacarbazine

Properties

Molecular Formula	C6H10N6O
Molecular Weight	182.18
Structure
State	solid
Route of elimination	Dacarbazine is subject to renal tubular secretion rather than glomerular filtration. In man, dacarbazine is extensively degraded. Besides unchanged dacarbazine, 5-aminoimidazole -4 carboxamide (AIC) is a major metabolite of dacarbazine excreted in the urine.
Protein binding	Less than 5%
Half life	5 hours
Absorption	Erratic, slow and incomplete.
Description	antineoplastic agent

Therapeutic Classification Source: DrugBank

L01AX04 Dacarbazine

[L01AX] Other alkylating agents

[L01A] ALKYLATING AGENTS

[L01] ANTINEOPLASTIC AGENTS

[L] Antineoplastic and immunomodulating agents

GHS Hazard Tables Source: PubChem

Pictogram	Signal	Statements	Precautionary Statement Codes
	Danger	Aggregated GHS information provided by 42 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H302+H312+H332 (90.48%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral acute toxicity, dermal acute toxicity, inhalation] H302 (92.86%): Harmful if swallowed [Warning Acute toxicity, oral] H312 (95.24%): Harmful in contact with skin [Warning Acute toxicity, dermal] H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H332 (95.24%): Harmful if inhaled [Warning Acute toxicity, inhalation] H335 (97.62%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure Respiratory tract irritation] H340 (95.24%): May cause genetic defects [Danger Germ cell mutagenicity] H350 (97.62%): May cause cancer [Danger Carcinogenicity] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.	P201, P202, P261, P264, P270, P271, P280, P281, P301+P312, P302+P352, P304+P312, P304+P340, P305+P351+P338, P308+P313, P312, P321, P322, P330, P332+P313, P337+P313, P362, P363, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Pictogram

Signal

Statements

Precautionary Statement Codes

Danger

Aggregated GHS information provided by 42 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

H302+H312+H332 (90.48%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral

acute toxicity, dermal

acute toxicity, inhalation]

H302 (92.86%): Harmful if swallowed [Warning Acute toxicity, oral]

H312 (95.24%): Harmful in contact with skin [Warning Acute toxicity, dermal]

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

H332 (95.24%): Harmful if inhaled [Warning Acute toxicity, inhalation]

H335 (97.62%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure

Respiratory tract irritation]

H340 (95.24%): May cause genetic defects [Danger Germ cell mutagenicity]

H350 (97.62%): May cause cancer [Danger Carcinogenicity]

Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.

P201, P202, P261, P264, P270, P271, P280, P281, P301+P312, P302+P352, P304+P312, P304+P340, P305+P351+P338, P308+P313, P312, P321, P322, P330, P332+P313, P337+P313, P362, P363, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Acute Effects Source: ChemIDplus

Organism	Test type	Route	Dose (normalized dose)	Source
rat	LD50	oral	2147mg/kg (2147mg/kg)	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9, Pg. 3105, 1981.
human	TDLo	intravenous	3500ug/kg (3.5mg/kg)	Cancer Chemotherapy Reports, Part 1. Vol. 57, Pg. 83, 1973.
rat	LD50	intravenous	411mg/kg (411mg/kg)	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9, Pg. 3105, 1981.
mouse	LD50	oral	2032mg/kg (2032mg/kg)	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9, Pg. 3105, 1981.
rat	LD50	intraperitoneal	350mg/kg (350mg/kg)	Archiv fuer Geschwulstforschung. Vol. 50, Pg. 306, 1980.
hamster	LD10	parenteral	250mg/kg (250mg/kg)	Journal of Surgical Oncology. Vol. 15, Pg. 355, 1980.
mouse	LD50	intraperitoneal	567mg/kg (567mg/kg)	Cancer Treatment Reports. Vol. 62, Pg. 721, 1978.
mouse	LD50	intravenous	466mg/kg (466mg/kg)	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9, Pg. 3105, 1981.

Indications Source: SIDER

Hodgkin's disease

Hodgkin's disease lymphocyte depletion type stage unspecified

Hodgkin's disease lymphocyte predominance type stage unspecified

Lymphoma

Malignant melanoma

Malignant neoplasm of islets of Langerhans

Medullary thyroid cancer

Metastatic malignant melanoma

Neoplasm malignant

Neuroblastoma

Non-Hodgkin's lymphoma

Sarcoma

Side effects Source: SIDER

Pancytopenia (0.25)

Vascular occlusion (1e-04)

Synonyms Source: PubChem

Dacarbazine

External IDs

DrugBank Name	Dacarbazine
DrugBank	DB00851
CAS Number	4342-03-4, 94361-71-4
PubChem Compound	135398738
KEGG Compound ID	C06936
KEGG Drug	D00288
PubChem.Substance	46507029
ChEBI	4305
PharmGKB	PA449197
ChemSpider	10481959
TTD	DAP000533
Wikipedia	Dacarbazine
DPD	2264